This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1990 Feb;22(1):60-3.

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression

A Zeevi¹, G Eiras, G Burckart, A Jain, A Kragack, R Venkataramanan, S Todo, J Fung, T E Starzl, R J Duquesnoy

Affiliations

PMID: 1689902
PMCID: PMC2903871

Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression

A Zeevi et al. Transplant Proc. 1990 Feb.

. 1990 Feb;22(1):60-3.

Authors

A Zeevi¹, G Eiras, G Burckart, A Jain, A Kragack, R Venkataramanan, S Todo, J Fung, T E Starzl, R J Duquesnoy

Affiliation

¹ Division of Clinical Immunopathology, School of Pharmacy, Prebyterian-University Hospital, University of Pittsburgh, PA 15213-2582.

PMID: 1689902
PMCID: PMC2903871

No abstract available

PubMed Disclaimer

Figures

Fig 1 — Fig 1
Standard curves of the FK 506 bioassay. The concentration of FK 506 is plotted versus percent Inhibition of PLT response of DB29 cells. The IC₅₀ was calculated using a nonlinear sigmoidal model fitted to the points.

Fig 2 — Fig 2
FK 506 levels in plasma measured by the bioassay and by the ELISA for liver transplant patients, (a) P2 and (b) P14.

See this image and copyright information in PMC

Similar articles

Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.
Zeevi A, Eiras G, Kaufman C, Alessiani M, Demetris AJ, Abu-Elmagd K, Jain A, Warty V, Venkataramanan R, Burckart G, et al. Zeevi A, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1406-8. Transplant Proc. 1991. PMID: 1703341 Free PMC article. No abstract available.
Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients.
Rudant E, Bezie Y, Bonhomme-Faivre L, Manuel N, Rucay P, Fredj G, Bismuth H. Rudant E, et al. J Clin Pharm Ther. 1997 Apr;22(2):135-40. doi: 10.1111/j.1365-2710.1997.tb00007.x. J Clin Pharm Ther. 1997. PMID: 9373812
Immunocompetence assay for net effect of combined immunosuppression.
Nagashima N, Shalabi A, Watanabe T, Ogawa N, Koyama I, Kyo S, Burdick JF. Nagashima N, et al. Transplant Proc. 2001 May;33(3):2350-1. doi: 10.1016/s0041-1345(01)02018-8. Transplant Proc. 2001. PMID: 11377556 No abstract available.
In vitro assessment of FK 506 immunosuppressive activity in transplant patients.
Zeevi A, Venkataramanan R, Warty V, Eiras G, Woan M, Abu-Elmagd K, Alessiani M, Jain A, Demetris AJ, Zerbe T, et al. Zeevi A, et al. Transplant Proc. 1991 Dec;23(6):2897-9. Transplant Proc. 1991. PMID: 1721307 Free PMC article. Review. No abstract available.
Clinical use of FK 506 in liver transplantation.
Klintmalm GB. Klintmalm GB. Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.

See all similar articles

Cited by

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.
Peters DH, Fitton A, Plosker GL, Faulds D. Peters DH, et al. Drugs. 1993 Oct;46(4):746-94. doi: 10.2165/00003495-199346040-00009. Drugs. 1993. PMID: 7506654 Review.
Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.
Zeevi A, Eiras G, Kaufman C, Alessiani M, Demetris AJ, Abu-Elmagd K, Jain A, Warty V, Venkataramanan R, Burckart G, et al. Zeevi A, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1406-8. Transplant Proc. 1991. PMID: 1703341 Free PMC article. No abstract available.
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
Christians U, Jacobsen W, Benet LZ, Lampen A. Christians U, et al. Clin Pharmacokinet. 2002;41(11):813-51. doi: 10.2165/00003088-200241110-00003. Clin Pharmacokinet. 2002. PMID: 12190331 Review.
The use of therapeutic drug monitoring to optimise immunosuppressive therapy.
Tsunoda SM, Aweeka FT. Tsunoda SM, et al. Clin Pharmacokinet. 1996 Feb;30(2):107-40. doi: 10.2165/00003088-199630020-00003. Clin Pharmacokinet. 1996. PMID: 8906895 Review.
Clinically significant drug interactions with new immunosuppressive agents.
Mignat C. Mignat C. Drug Saf. 1997 Apr;16(4):267-78. doi: 10.2165/00002018-199716040-00004. Drug Saf. 1997. PMID: 9113494 Review.

See all "Cited by" articles

References

1. Starzl TE. Transplant Proc. 1988;20(suppl 3):356. - PMC - PubMed
1. Starzl TE, Todo S, Fung J, et al. Lancet. 1989;2:1000. - PMC - PubMed
1. Ochiai T, Nakajima K, Nagata M, et al. Transplant Proc. 1987;19:1284. - PubMed
1. Zeevi A, Duquesnoy RJ, Eiras G, et al. Transplant Proc. 1987;19(suppl 6):40. - PMC - PubMed
1. Sawada S, Suzuki G, Kawase Y, et al. J Immunol. 1897;138:1797. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information